Tango Therapeutics, Inc. (TNGX)
Automate Your Wheel Strategy on TNGX
With Tiblio's Option Bot, you can configure your own wheel strategy including TNGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TNGX
- Rev/Share 0.3716
- Book/Share 1.5118
- PB 1.4684
- Debt/Equity 0.2216
- CurrentRatio 6.2625
- ROIC -0.6053
- MktCap 240634680.0
- FreeCF/Share -1.2325
- PFCF -1.77
- PE -1.8514
- Debt/Assets 0.1347
- DivYield 0
- ROE -0.6275
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.
Read More
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. “Accumulating data …
Read More
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. …
Read More
About Tango Therapeutics, Inc. (TNGX)
- IPO Date 2020-09-03
- Website https://www.tangotx.com
- Industry Biotechnology
- CEO Dr. Barbara L. Weber M.D.
- Employees 155